Eli Lilly earnings beat by $0.18, revenue topped estimates

Investing.com – Eli Lilly (NYSE: ) reported fourth quarter EPS of $2.49, $0.18 better than the analyst estimate of $2.31. Revenue for the quarter came in at $9.35B versus the consensus estimate of $8.95B.

Guidance

Eli Lilly sees FY 2024 EPS of $12.20-$12.70 versus the analyst consensus of $12.38.

Eli Lilly sees FY 2024 revenue of $40.40B-$41.60B versus the analyst consensus of $39.14B.

Eli Lilly’s stock price closed at $705.86. It is up 19.37% in the last 3 months and up 107.80% in the last 12 months.

Eli Lilly saw 0 positive EPS revisions and 15 negative EPS revisions in the last 90 days. See Eli Lilly’s stock price’s past reactions to earnings here.

According to InvestingPro, Eli Lilly’s Financial Health score is “good performance”.

Check out Eli Lilly’s , and Eli Lilly’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar